Stonebridge Financial Group (Pennsylvania)’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.12M Buy
8,747
+81
+0.9% +$9.48K 0.09% 122
2026
Q1
$1.04M Buy
8,666
+843
+11% +$97.3K 0.09% 122
2025
Q4
$823K Buy
7,823
+225
+3% +$21.1K 0.07% 127
2025
Q3
$638K Sell
7,598
-25,113
-77% -$2.07M 0.06% 139
2025
Q2
$2.59M Sell
32,711
-14,293
-30% -$1.14M 0.25% 90
2025
Q1
$4.22M Buy
47,004
+6,025
+15% +$563K 0.45% 62
2024
Q4
$4.08M Buy
+40,979
New +$4.22M 0.45% 62

Other funds holding MRK

Stonebridge Financial Group (Pennsylvania)'s MRK Position: Q2 2026 in Review

Stonebridge Financial Group (Pennsylvania) increased its Merck (MRK) stake by 0.93% in Q2 2026, buying an estimated $9.48K and bringing the position to 8,747 shares worth $1.12M. The position accounts for 0.09% of the portfolio, ranked #122.

Stonebridge Financial Group (Pennsylvania) first reported a position in MRK in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.22M in Q1 2025. 3,344 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Stonebridge Financial Group (Pennsylvania) held 8,747 shares of Merck worth $1.12M as of Q2 2026.
  • Stonebridge Financial Group (Pennsylvania) bought 81 Merck shares in Q2 2026, an estimated $9.48K.
  • Merck made up 0.09% of Stonebridge Financial Group (Pennsylvania)'s portfolio in Q2 2026, its #122 holding.
  • Stonebridge Financial Group (Pennsylvania) first reported a position in Merck in Q4 2024 and has held it in 7 quarters since.
  • Stonebridge Financial Group (Pennsylvania)'s Merck position peaked at $4.22M in Q1 2025.
  • 3,344 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Stonebridge Financial Group (Pennsylvania)'s 13F filing for Q2 2026, filed 6 Jul 2026.